CTIX is developing non-toxic medications for 'drug-resistant' cancers and high blood pressure conditions, etc., that have already proven to be very effective in their multiple and continuing animal trials. Per the EDGAR From 3s, the three primary company executives (and members of their families) hold most of the issued stock. Hence, the PPS seems to move up quickly when any buying occurs. There are only three Market Makers in the mix, and 100+/- stockholders the last time I looked. Those numbers chould all improve soon. There were no Form 4s, so no one inside is selling. It's obviously a development stage company, so I'm sure the Q's will give TA gurus some heartburn at this point.
The Bid-Ask spread will probably tighten up as volume increases when their IR/PR efforts begin and trading volume increases. IMHO, anywhere under $1 is a Buy & Hold value. There's no reason that CTIX, like NNVC, couldn't go to $2+ reasonably soon as a little more effort is put into getting the word out medically=professionally as well as to the public.
Since most cancer treatment cocktails are toxic-to-poisonous, CTIX's non-toxic offerings could be a major step forward and offer considerable relief to patients (i.e.: no loss of hair, reduced nausea, etc., etc). Medical stocks and pharmaceuticals are not my specialty at all, so those with more involvement should dig into the possibilities. But, CTIX seems to have a lot of promise.
Their CSO, Dr. Menon, seems to have pretty good credentials. I believe they plan to provide their materials to other current drug manufacturers to reduce toxicity and raise the efficacy of current drug formulations in addition to developing-marketing their own. Partnerships and synergies with existing players would seem to make the pharma approval process much easier.
It's worth a good look anyway, IMHO, since their PPS has gone from 0.20+/- to $1 on just a few buys lately. Improved volume will obviously cause the numbers and spreads to even out.
. |
